A phase 1B open-label clinical trial to expand the characterization of the immune responses to the Merck adenovirus serotype 5 HIV-1 Gag/pol/nef vaccine [V 520] in healthy, HIV-1 uninfected adult participants.

Trial Profile

A phase 1B open-label clinical trial to expand the characterization of the immune responses to the Merck adenovirus serotype 5 HIV-1 Gag/pol/nef vaccine [V 520] in healthy, HIV-1 uninfected adult participants.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2013

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2008 Planned end date changed from 1 Sep 2007 to 1 May 2012, as reported by ClinicalTrials.gov.
    • 22 Sep 2007 Status changed from initiated to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top